NCT03782636 (ITAD) is a Phase 2 clinical trial of Aldesleukin in Type1 Diabetes, sponsored by University of Oxford.

Who is sponsoring NCT03782636?

NCT03782636 is sponsored by University of Oxford.

What drugs are being tested in NCT03782636?

Interventions in NCT03782636: Aldesleukin, Placebo.

What condition does NCT03782636 study?

NCT03782636 studies Type1 Diabetes.

Is NCT03782636 still recruiting?

NCT03782636 is currently active, enrolled. Last updated 29 September 2025.

Last reviewed 2025-09-29 · How we verify

NCT03782636: ITAD

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Interleukin-2 Therapy of Autoimmunity in Diabetes (ITAD)

Active, enrolled Phase 2 Last updated 29 September 2025

What this trial tests

Phase 2 trial testing Aldesleukin in Type1 Diabetes in 41 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

28 January 2019

Primary endpoint
16 February 2023

1 September 2026

Quick facts

Lead sponsor	University of Oxford
Phase	Phase 2
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	41
Start date	28 January 2019
Primary completion	16 February 2023
Estimated completion	1 September 2026
Sites	5 locations across United Kingdom

Drugs / interventions tested

Aldesleukin (ALDESLEUKIN) — full drug profile →
Placebo

Conditions studied

Type1 Diabetes — all drugs for Type1 Diabetes →

Sponsor

University of Oxford

Who can join

Adults 6 to 18, any sex, with Type1 Diabetes. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Differences in slopes of DBS (Dried Blood Spot) C-peptide over the 6 month-treatment period between the active and placebo groups.
Time frame: Weekly DBS C-peptide collected during the 6-month treatment period, and then monthly during the 6 months of follow-up

Sponsor's own description

The main purpose of this study is to see if a drug called aldesleukin, can preserve insulin production in children and young adults recently diagnosed with type 1 diabetes. One group will receive aldesleukin and the other a placebo.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Rebalancing Immune Homeostasis to Treat Autoimmune Diseases.
Horwitz DA, Fahmy TM, Piccirillo CA, La Cava A. · · 2019 · cited 87× · PMID 31601519 · DOI 10.1016/j.it.2019.08.003
Low-dose IL-2 reduces IL-21<sup>+</sup> T cell frequency and induces anti-inflammatory gene expression in type 1 diabetes.
Zhang JY, Hamey F, Trzupek D, Mickunas M, et al · · 2022 · cited 23× · PMID 36443294 · DOI 10.1038/s41467-022-34162-3
Strategies to Use Nanoparticles to Generate CD4 and CD8 Regulatory T Cells for the Treatment of SLE and Other Autoimmune Diseases.
Horwitz DA, Bickerton S, La Cava A. · · 2021 · cited 20× · PMID 34211471 · DOI 10.3389/fimmu.2021.681062
Therapeutic Strategies for Diabetes: Immune Modulation in Pancreatic β Cells.
Jo S, Fang S. · · 2021 · cited 18× · PMID 34484126 · DOI 10.3389/fendo.2021.716692
Interleukin-2 Therapy of Autoimmunity in Diabetes (ITAD): a phase 2, multicentre, double-blind, randomized, placebo-controlled trial.
Marcovecchio ML, Wicker LS, Dunger DB, Dutton SJ, et al · · 2020 · cited 18× · PMID 32399500 · DOI 10.12688/wellcomeopenres.15697.1

Verify or expand the search:

Other trials of Aldesleukin

Trials testing the same drug.

NCT07389239 — A Study Evaluating the Immunotherapy Treatment for Ovarian Cancer and Other Advanced Malignancies. · Phase 1, PHASE2 · not yet recruiting
NCT06626256 — STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Colorectal Ca · Phase 1 · withdrawn
NCT06690281 — A Phase II Study of Adjuvant Immunotherapy Targeting KRAS G12D, KRAS G12V, or TP53 R175H for Participants With Advanced · Phase 2 · withdrawn
NCT05639972 — E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers · Phase 1, PHASE2 · recruiting
NCT05989828 — A2-ESO-1 TCR-Engineered T Cells for Relapsed/Refractory Advanced or Metastatic NY-ESO-1 Overexpression Positive Triple N · Phase 1 · suspended

Other recruiting trials for Type1 Diabetes

Currently open trials in the same condition.

NCT06408207 — CGM Academy for Youth With Type 1 Diabetes · NA · recruiting

Other University of Oxford trials

Trials by the same sponsor.

NCT05380388 — A Safety, Immunogenicity and Efficacy Study of PvRII/Matrix-M in Healthy Thai Adults Living in Thailand ( MIST3 ) · Phase 2 · not yet recruiting
NCT07470424 — A Clinical Study of Piperaquine, Pyronaridine, and Artesunate Administered in Combination in Healthy Adults · Phase 1 · not yet recruiting
NCT07345910 — Environment, Pathogens, and Host Interactions in Melioidosis · not yet recruiting
NCT07434973 — Stratification and Treatment in Early Psychosis Study - PROMOTE · Phase 3 · not yet recruiting
NCT07460401 — 'Do Patient Characteristics Associate With Poor Outcome With Femoral Acetabular Impingement Syndrome (FAIS) Following Ph · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03782636 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Oxford
Last refreshed: 29 September 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03782636.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing